This research develops an inhalable treatment for lung infections using nanocrystalline silver with both antimicrobial and anti-inflammatory properties. By adapting proven skin-based technology for respiratory delivery via nebulization, it targets both pathogens and harmful inflammation, addressing a major gap in lung disease treatment affecting over a billion people worldwide.

Acute respiratory distress syndrome (ARDS) causes severe breathing failure and kills tens of thousands annually, yet has no effective treatment. This research studies how ARDS disrupts lung surfactant, a critical stabilizing substance in the lungs. By identifying immune-related factors that damage surfactant, the work aims to develop the first targeted therapeutic cure.